Detalhe da pesquisa
1.
Cetuximab plus carboplatin and paclitaxel with or without bevacizumab versus carboplatin and paclitaxel with or without bevacizumab in advanced NSCLC (SWOG S0819): a randomised, phase 3 study.
Lancet Oncol
; 19(1): 101-114, 2018 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29169877
2.
A phase I-II evaluation of veliparib (NSC #737664), topotecan, and filgrastim or pegfilgrastim in the treatment of persistent or recurrent carcinoma of the uterine cervix: an NRG Oncology/Gynecologic Oncology Group study.
Int J Gynecol Cancer
; 25(3): 484-92, 2015 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-25594147
3.
Phase II evaluation of sorafenib in advanced and metastatic squamous cell carcinoma of the head and neck: Southwest Oncology Group Study S0420.
J Clin Oncol
; 28(20): 3330-5, 2010 Jul 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-20498388
4.
Bortezomib (PS-341) in relapsed or refractory extensive stage small cell lung cancer: a Southwest Oncology Group phase II trial (S0327).
J Thorac Oncol
; 1(9): 996-1001, 2006 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-17409985